Alendronic acid: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Alendronic acid: clinical details
Prescribing considerations
- Confirm that the patient can follow administration instructions and remain upright.
- Correct hypocalcaemia and address vitamin D deficiency or other mineral-metabolism disorders before initiation.
- Assess renal function, upper gastrointestinal disease and oesophageal symptoms.
- Review dental status and osteonecrosis risk factors; encourage oral hygiene and routine dental care.
- Ensure adequate calcium and vitamin D intake where dietary intake is insufficient.
- Periodically reassess fracture benefit and treatment risks.
Contraindications and cautions
- Oesophageal abnormalities or other factors delaying oesophageal emptying, including stricture or achalasia.
- Inability to sit or stand upright for at least 30 minutes.
- Hypocalcaemia.
- Hypersensitivity to alendronic acid or an excipient.
- The selected tablet contains lactose and is unsuitable in specified rare hereditary disorders of galactose metabolism or absorption.
Monitoring
- Renal function before treatment and when clinically indicated; the selected product is not recommended when creatinine clearance is below 35 mL/min.
- Calcium and symptoms of hypocalcaemia in patients with risk factors.
- New dysphagia, odynophagia, retrosternal pain or worsening heartburn.
- Oral symptoms, dental mobility and planned invasive dental procedures.
- New thigh, hip or groin pain.
- Persistent ear pain, discharge or recurrent infection, considering external auditory canal osteonecrosis.
Clinical pharmacology
Alendronate is a nitrogen-containing bisphosphonate that localises at sites of active bone resorption and inhibits osteoclast activity without directly suppressing bone formation. Oral absorption is very low and is further reduced by food, drinks and several oral medicines. It is not metabolised; unbound drug is excreted renally, while skeletal drug is released slowly over time.
Formulation and product differences
- The selected product is a conventional tablet that must be swallowed whole and contains lactose.
- Other UK products include soluble tablets and oral liquids; preparation-specific administration instructions are not interchangeable.
Alendronic acid preparations and strengths
Tablet
Route: Oral
Strengths: 70 mg
Alendronic acid interactions
Food, drinks and several oral products can substantially reduce absorption. Important examples include:
Calcium, iron, magnesium or zinc supplements
They interfere with alendronic acid absorption and should not be swallowed at the same time.
Antacids and magnesium-containing laxatives
They reduce absorption when taken at the same time.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.